Beyond the product

The data measuring the problem, the intellectual property status, and the path to market.

The problem is real and measurable

Direct observation revealed a need. Public data on therapy adherence revealed its scale: a systemic problem that affects millions of chronic patients every year and that has guided every design decision in Omiari.

9.6 million

over-65s in Italy take 5 or more different medications during the year (68% of the elderly population)

50%

of patients globally do not follow therir therapy as prescribed

33-69%

of relapses in chronic patients globally caused by non-adherence

16-50%

of hypertensive patients in OECD countries discontinue their medications within the first year of treatment

200,000

premature deaths every year in the EU due to poor adherence

€125 billion

estimated annual cost for European health systems due to poor medication adherence; €2 billion in Italy

Sources:
World Health Organization, Adherence to Long-Term Therapies: Evidence for Action, 2003.
OECD, Investing in Medication Adherence Improves Health Outcomes and Health System Efficiency, 2018.
AIFA, L'uso dei Farmaci in Italia - Rapporto OsMed 2023.
AIFA, Press release no. 23/2024 — Poor therapy adherence costs two billion per year, 11 November 2024.

The scale of the problem guides every design decision. Omiari responds with an industrializable, protected solution.

The target market

Three access channels with distinct operational characteristics, in a growing European sector.

Family and caregivers

7.3Mactive family caregivers in Italy for elderly and chronic patients. Primary adoption channel for the home device.

Residential facilities

8,045socio-healthcare residential facilities in Italy (nursing homes, disability facilities, mental health). B2B channel with centralized pharmacological therapy management.

Pharmacies

20,160pharmacies in Italy. The pharmacist becomes an active node of the ecosystem: cartridge pickup, customization and adherence monitoring.

European digital health

$66.2BEuropean market size in 2023, with an expected CAGR of 22.3% between 2024 and 2030.

Sources:
ISTAT, Condizioni di salute e ricorso ai servizi sanitari in Italia e nell'Unione europea, EHIS 2019.
Ministry of Health, Annuario Statistico del Servizio Sanitario Nazionale, 2022.
Federfarma, La farmacia italiana 2025.
Assolombarda, Digital Health Revolution 2022-2024.

Protected intellectual property

The Omiari project is supported by a solid intellectual property foundation. A first Italian patent for industrial invention has already been obtained and others are being released. The international PCT has had a 100% positive outcome.

Yoovant is seeking partners and investors in the pharma and medtech sectors to bring Omiari to market.

Italian patents

A first patent for industrial invention already obtained, others filed and being released.

International PCT

Patent Cooperation Treaty with a 100% positive verification report. No requests for additional information from the examiner.

The road traveled. And what remains.

From the first concept to the patent obtained: every milestone is the result of methodical work. The next steps define the path to market.

Percorso

Jan 2024

Needs analysis and market research

Feb 2024

Home device concept

Mar 2024

1st patent application (Italy)

May 2024

Pharmacy ecosystem concept

Sep 2024

Iterative prototyping

6v body · 10v cartridge

Oct 2024

Non-negative search report

Mar 2025

2nd patent with priority + PCT

Sep 2025

100% positive PCT · Software development begins

Feb 2026

First patent obtained

Apr 2026

Orizzonte

Aug 2026

PCT · regional and national phases begin

H2 2026

Home device firmware beta

Q3 2027

Omiari LAB prototype

Q4 2027

iOS app beta · Amazon Alexa Skill

H1 2028

Pilot with partner pharmacies (Omiari Lab manual)

H2 2028

Italy launch (Omiari Lab automatic)

2029

EU expansion · Nursing homes and pharmacies